David Ricks, CEO of Eli Lilly, noted on the 14th (local time) during a presentation at the 43rd JPMorgan Healthcare Conference (JPM 2025) held at The Westin St. Francis in San Francisco ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 ...

Eli Lilly & Co., the Fortune 500 pharma firm that ... in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025. · Fortune · Gam1983 ...

According to a Bloomberg report, Meta CEO Mark Zuckerberg said in an internal memo that he had "decided to raise the bar on performance management and move out low-performers faster".

"We know the supply chain, PBMs are not transparent enough and we should be able to pass through more of that savings directly to consumers," Eli Lilly CEO David Ricks said during a presentation ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and with caution. As the creator of the blockbuster weight-loss drug Zepbound, and ...

Good afternoon, everybody. I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...